tldrdailynews.com logo
Tag

Takeda

All articles tagged with #takeda

Takeda's R&D Chief Andy Plump to Retire, Sparking Leadership Transition
business28 days ago

Takeda's R&D Chief Andy Plump to Retire, Sparking Leadership Transition

Takeda says longtime R&D chief Andy Plump will retire in June, staying on through a transition to a successor as the company pursues new growth drivers after Entyvio's loss of exclusivity. The move comes amid recent FDA approvals for Orzeyful and Mimrylo and positive data on zasocitinib, while past initiatives such as GammaDelta’s cell therapy and Alofisel have faced setbacks, underscoring the need for a continued push to diversify the pipeline.

via Fierce Biotech|
#andy-plump#business#drug-approvals
FDA approves Takeda narcolepsy drug, signaling a new era for orexin-based therapies
health2 months ago

FDA approves Takeda narcolepsy drug, signaling a new era for orexin-based therapies

The FDA approved Takeda’s Orzeyful, a twice-daily orexin receptor agonist for narcolepsy type 1, a first-in-class treatment that improved daytime wakefulness and reduced sleepiness in Phase 3 trials, offering potential benefits over current therapies and hinting at broader neurological applications, though long-term safety and applicability remain under study.

via STAT|
#fda-approval#health#narcolepsy
Takeda's TYK2 rival tops Sotyktu in psoriasis trial, eyeing 2027 launch
business4 months ago

Takeda's TYK2 rival tops Sotyktu in psoriasis trial, eyeing 2027 launch

Takeda's TYK2 inhibitor zasocitinib beat Bristol Myers Squibb's Sotyktu in a Phase 3 head-to-head for moderate-to-severe plaque psoriasis, delivering PASI 100 in over 35% of patients at Week 16 and outperforming on key secondary endpoints with a favorable safety profile; Takeda plans a first-half 2027 launch, signaling continued pressure on Sotyktu as its sales have underperformed since its 2022 approval.

via Fierce Biotech|
#business#psoriasis#sotyktu
Takeda trims U.S. workforce in $1.3B restructuring to boost efficiency
business6 months ago

Takeda trims U.S. workforce in $1.3B restructuring to boost efficiency

Takeda is cutting about 634 U.S. roles (247 in Massachusetts, 387 elsewhere) as part of a $1.26 billion, multi-year restructuring to boost efficiency. Notices began now with changes taking effect in July 2026, allowing redeployment where possible. The savings will be funneled into upcoming launches and R&D while the company also consolidates its U.S. footprint.

via Fierce Pharma|
#business#cost-savings#layoffs
Mortal Kombat 1: Takeda DLC Gameplay Revealed, Releases July 23
gaming2 years ago

Mortal Kombat 1: Takeda DLC Gameplay Revealed, Releases July 23

NetherRealm has released a gameplay trailer for Mortal Kombat 1's final Year 1 DLC character, Takeda, showcasing his bladed whips and fatality ahead of his July 23 release. Takeda, a former Yakuza turned Shirai Ryu warrior, joins other DLC characters like Omni-Man and Homelander. The reveal precedes a Comic-Con 2024 panel where Year 2 plans for Mortal Kombat 1 will be discussed.

via IGN|
#comic-con#dlc#gameplay-reveal
"Brazil Launches Groundbreaking Mass Dengue Vaccination Campaign"
health2 years ago

"Brazil Launches Groundbreaking Mass Dengue Vaccination Campaign"

Dourados, a city in Brazil's Mato Grosso do Sul state, has started the country's first mass vaccination campaign against dengue using Takeda's vaccine, QDENGA. The campaign aims to vaccinate 150,000 residents aged between 4 and 59, with the first batch of 90,000 doses already distributed. This follows a rise in dengue cases and deaths in Brazil, with 1.6 million cases and 1,053 deaths reported in 2023. The vaccine will be included in Brazil's national vaccination program but will initially focus on priority groups due to limited supply.

via Reuters Canada|
##aedesaegypti#brazil
Mortal Kombat 1 Leaks Unveil Surprising Takeda Origin and DLC Wishlist Fulfillment
gaming3 years ago

Mortal Kombat 1 Leaks Unveil Surprising Takeda Origin and DLC Wishlist Fulfillment

A leak from Mortal Kombat 1 suggests that Takeda, a character from MKX, will have a different origin in the rebooted timeline. The leaked voice lines indicate that Takeda is no longer Kenshi's son but rather his cousin. While this information should be taken with caution, if true, it will be interesting to see how this altered family dynamic affects the Takahashi clan. Concrete details about Takeda's new origin may not be revealed for some time, as he is not expected to arrive until Summer 2024.

via Dexerto|
#family-dynamic#gaming#kenshi
Takeda invests in celiac disease drug development with antibody licensing and conjugate development.
pharmaceuticals3 years ago

Takeda invests in celiac disease drug development with antibody licensing and conjugate development.

Takeda has signed a licensing deal with Innate Pharma to use a panel of antibodies to research and develop antibody-drug conjugates (ADCs) for celiac disease. In exchange for exclusive worldwide rights to whatever ADCs are developed using a selection of Innate’s antibodies, Takeda will give Innate a $5 million upfront payment with the potential for $410 million in milestones, plus royalties on net sales of any product resulting from the license.

via Endpoints News|
#adcs#celiac-disease#innate-pharma